| Literature DB >> 32842529 |
Nair Silva Macêdo1,2, Zildene de Sousa Silveira1,2, Antonio Henrique Bezerra1, José Galberto Martins da Costa3, Henrique Douglas Melo Coutinho4, Barbara Romano5, Raffaele Capasso6, Francisco Assis Bezerra da Cunha1, Márcia Vanusa da Silva2.
Abstract
Caesalpinia ferrea C. Mart., popularly known as "Jucá" or "Pau-ferro", belongs to the Fabaceae family, and is classified as a native and endemic species in Brazil. Numerous studies that portray its ethnobotany, chemical composition, and biological activities exist in the literature. The present study aimed to systematically review publications addressing the botanical aspects, uses in popular medicine, phytochemical composition, and bioactivities of C. ferrea. The searches focused on publications from 2015 to March 2020 using the Scopus, Periódicos Capes, PubMed, Google Scholar, and ScienceDirect databases. The leaves, fruits, seeds, and bark from C. ferrea are used in popular medicine to treat disorders affecting several systems, including the circulatory, immune, cardiovascular, digestive, respiratory, genitourinary, musculoskeletal, and conjunctive systems. The most commonly found chemical classes in phytochemical studies are flavonoids, polyphenols, terpenoids, tannins, saponins, steroids, and other phenolic compounds. The biological properties of the extracts and isolated compounds of C. ferrea most cited in the literature were antibacterial, antifungal, antioxidant, antiproliferative, anti-inflammatory, and healing potential. However, further studies are still needed to clarify a link between its traditional uses, the active compounds, and the reported pharmacological activities, as well as detailed research to determine the toxicological profile of C. ferrea.Entities:
Keywords: Caesalpinia ferrea; HPLC; bioactivities; ethnoknowledge; phytochemicals
Mesh:
Substances:
Year: 2020 PMID: 32842529 PMCID: PMC7503918 DOI: 10.3390/molecules25173831
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Summary of the C. ferrea botanical characteristics.
| Characteristics | Attributes | Citations |
|---|---|---|
| Habit | Arboreal | [ |
| Height | 10–15 m | [ |
| Leaves | Alternating and composed | [ |
| Flowers | Inflorescences with yellow petals | [ |
| Fruits | Flattened pods | [ |
| Seeds | Brown when ripe | [ |
Traditional uses of C. ferrea for curing diseases.
| Part Used | Method of Preparation or Use | Therapeutic Indication | Citation |
|---|---|---|---|
| Leaf | Tea | Vermifuge | [ |
| Leaf, bark and fruit | Decoction, “lambedor”, maceration, medicinal wine | Asthma, bones pain, flu, kidney pain, cough, shaking | [ |
| Bark | Decoction | Liver/bleeding | [ |
| Pod, fruit, seed, and bark | Tanned in wine, tea, bath, macerated, cooked beaten with water | Anti-inflammatory and healing | [ |
| Bark and fruit | Tea, “lambedor” and syrup | Flu, kidney inflammation and soothing | [ |
| Fruit | “Lambedor” | Flu | [ |
| Bark and seeds | Hurt the seed and soak it in the water | Pneumonia, anemia, diarrhea, colic and gastritis | [ |
| Stem bark, fruit, and seed | Maceration | Anti-inflammatory, kidneys, bruises, back pain, healing, analgesic | [ |
| Bark | Decoction | Malaria | [ |
| Bark and root | Tea and bottles | Rheumatism and diabetes | [ |
| Bark and fruit | Bottles | Anti-inflammatory | [ |
| Fruit | Tea | Diarrhea, liver and healing | [ |
| Stalk | Tea | Anti-inflammatory | [ |
| Roots | Decoction | Hemorrhoids, inflammation of the eyes and injuries | [ |
| Whole shell | Immersed in water | Hemorrhage, anti-inflammatory, infection and pain | [ |
| Dry bark | Decoction | Back pain | [ |
| Stem bark and fruit | Maceration and cooking | Back pain, vision problems, anti-inflammatory and healing | [ |
| Fruit | Tea (decoction), tea (maceration), maceration in a bath | Sore throat, hoarseness, leg pain, toothache, uterine inflammation, wounds, anemia, gastritis | [ |
| Fruit, bark, roots and seed | Tea and tincture | Asthma, bronchitis, flu, fever, sore throat, sinusitis, diarrhea, rheumatism, blood clearance, kidneys and soothing | [ |
| Fruits | Tea | Urinary infection | [ |
| Fruits | Bottles | Infection | [ |
| Stem bark, bast, fruits and seeds | Tea, “lambedor”, | Infectious diseases, parasitic, circulatory, immune, cardiovascular, digestive, respiratory, genitourinary, musculoskeletal, conjunctive, injuries and poisoning | [ |
| Seeds | Tea and immersed in water | Skin cuts, cough, flu and depression | [ |
| Bark, fruit, and seeds | Decoction, infusion, maceration and syrup | Syphilis, cancer, depurative, diabetes, asthma, gastritis, bronchitis, sinusitis, stomach ache, rheumatism, sexual impotence, healing, bone fracture, headache, fever and throat infection | [ |
| Whole plant and fruits | Infusion and maceration | Spine, blow, inflammation and kidneys | [ |
| Leafs | Tea | All kinds of infection and inflammation | [ |
Chemical classes or constituents found in C. ferrea extracts.
| Part Used | Solvent | Analytical Technique | Constituents | Citations |
|---|---|---|---|---|
| Leafs | Cyclohexane | CG/MS | Octacosane, docosane, and heptacosan | [ |
| Leafs | Water | HPLC | Ellagic acid and gallic | [ |
| Leafs | Water at 25 and 100 °C | HPLC-DAD | Gallic acid, caffeic and ellagic epicatechin, quercetin, and luteolin and catechin | [ |
| Leafs | Ethanol at 70% | HPLC | Ellagic acid and gallic, orientin and isovitexin | [ |
| Leafs | Ethanol at 70% | NMR 1D e 2D | Gallic acid, brevifolin carboxylic acid, and brevifolin | [ |
| Barks and seeds | Ethanol at 70% | HPLC | Ellagic acid | [ |
| Barks | Water at 25 and 100 °C | HPLC-DAD | Gallic, caffeic and ellagic acids, catechin, epicatechin and quercetin | [ |
| Barks | Water | RP-HPLC | Ellagic acid and gallic | [ |
| Barks | Ethanol and water | LC-MS/MS | Kaempferol, quinolinic acid and gallic | [ |
| Fruit | Ethanol at 96% | LC-HRMS/MS | Corilagin and ellagic acid and gallic | [ |
| Fruit | Water, ethanol at 20–80% | HPLC-DAD | Ellagic acid and gallic | [ |
| Fruit | Ethanol | HPLC | Ellagic acid and gallic | [ |
| Fruit | Water | HPTLC e HPLC | Ellagic acid and gallic | [ |
| Pods | N-hexane | GC-MS | N-dodecanol, myristic acid, methyl palmitate, palmitic acid | [ |
| Pods | Chloroform | GC-MS | n-valeric acid, caproic acid, heptanoic acid, and octanoic acid | [ |
| Pods | Ethyl acetate | GC-MS | Oxalic acid, butanedioic acid, pyrotartaric acid, and pentanoic acid | [ |
| Pods | Alcohol at 70% | GC-MS | Glycerol, D-fructose, myo-inositol, and glucopyranose | [ |
| Pods | Alcohol at 40% | HPLC-MS | Valonium dilactone acid, gallic acid derivatives, and ellagic acid | [ |
| Pods | Ethanol and Water | LC-MS/MS | Ellagic acid, chlorogenic acid, and rutin | [ |
| Pods | Water at 25 and 100 °C | HPLC-DAD | Ellagic acid and gallic, catechin, epicatechin, quercetin, and luteolin | [ |
GC-MS = thin-layer chromatography and Gas Chromatography-Mass Spectrometry; HPLC-DAD = High-Performance Liquid Chromatography with Diode Array Detection; RP-HPLC = Reverse Phase High-Performance Liquid Chromatography; HPLC = High Performance Liquid Chromatography; LC-HRMS/MS = Liquid Chromatography-High Resolution Tandem Mass Spectrometry; NaOH = Sodium hydroxide; LC-MS/MS = Liquid Chromatography Coupled to Tandem Mass Spectrometry; HPLC-MS = High-Performance Liquid Chromatography coupled to Mass Spectrometry; HPTLC = High-Performance Thin Layer Chromatography; NMR = Nuclear Magnetic Resonance.
Figure 1Chemical structures of the main compounds from C. ferrea. Ellagic acid: C14H6O8 and MW: 302.19 g/mol; Gallic acid: C7H6O5 and MW: 170.12 g/mol; Heptacosan: C27H56O and MW: 396.7 g/mol; Galactomannan: C18H32O16 and MW: 504.4g/mol; Kaempferol: C15H10O6 and MW: 286.24 g/mol; 2”-O-Galloylorientin: C28H24O15 and MW: 600.5 g/mol; 2”-O-Galloylvitexin: C28H24O14 and MW: 584.5 g/mol; Glycerol: C3H8O3 and MW: 92.09 g/mol.
Bioactivities evaluated with different extracts of C. ferrea.
| Parts Used/Solvents | Target or Model | Bioactivities Evaluated | Formulations/Dosage | Control (s) | Results | Citations |
|---|---|---|---|---|---|---|
| Full pod/Methanol | Antibacterial and anti-halitosis | In vitro | Positive: chlorhexidine | MIC: 50 and 120 µg/mL, respectively MBC: >50 and 130 µg/mL, respectively | [ | |
| Leafs/ | Antibacterial | In vitro | Positive: ampicillin | MIC: 0.039, 0.039, 0.039, 0.39, 0.078 mg/mL, respectively | [ | |
| Leafs/Chloroform | Antibacterial | In vitro | Positive: ampicillin | MIC: 1.56, 6.25, 12.5, 3.12, 0.78 mg/mL, respectively | [ | |
| Leafs/Ethyl acetate | Antibacterial | In vitro | Positive: ampicillin | MIC: 0.78, 6.25, 12.5, 3.12, 1.56 mg/mL, respectively | [ | |
| Leafs/Methanol | Antibacterial | In vitro | Positive: ampicillin | MIC: 6.25, 12.5, 25, 3.12, 3.12 mg/mL, respectively | [ | |
| Barks/Alcohol | Antibacterial and healing activity | In vitro | Negative: bacterial nanocellulose membranes with extract | MIC: 0.39, 0.79 and 0.19 mg·mL−1, respectively | [ | |
| Fruits/Alcohol | Antibacterial | In vitro | Negative: sterile water | Inhibition halos: 18, 12, 10 and 11 mm, respectively | [ | |
| Leafs and Fruits/Water |
| Antibacterial | In vitro | Negative: water | 70% inhibition at a concentration of 0.4 mg/mL | [ |
| Pods and bark/Ethanol | Antibacterial | In vitro | Positive: amikacin, gentamicin, and clindamycin | MIC: 1024 µg/mL for all strains | [ | |
| Barks/Alcohol | Antibacterial | In vitro | Positive: ampicillin, cephalexin, gentamicin, oxacillin, and penicillin | Inhibition halos: 61.1; 27.78 and 5.56% for the crude extract and concentrations of 70 and 50%, respectively | [ | |
| Leafs/ | Antibacterial | In vitro | Negative: liquid soap | Average inhibition halo: 0.97 cm | [ | |
| Pods/Ethanol | Antibacterial | In vitro | Positive: chlorhexidine gluconate | MIC: 15, 14, 14, 15, 15 mg/mL, respectively, and MICA: 31.2 mg/mL for all strains | [ | |
| Pods/Ethanol | Antibacterial and antioxidant | In vitro | Positive: ascorbic acid and Trolox. | MIC: 125, 50, 50, 50, 125, 50 μg/mL, respectively; DPPH: EC50 4.4 μg/mL and ABTS: EC50 2.5 μg/mL | [ | |
| Pods/Alcohol | Antibacterial, antioxidant, antiulcerogenic and toxicity | In vitro | Positive: amoxicillin, trolox, ranitidine, respectively. | MIC: 512 µg/mL; DPPH and ABTS: IC50 of 28.96 and 145.10 μg/mL, respectively; ED: 113 and 185.7 mg/kg; LD greater than 2000 mg/kg | [ | |
| Pods | Proteobacteria and Bacteroidetes | Antibiofilm | In vitro | Negative: sterile water | Inhibited growth by 82% at a concentration of 4 mg·mL−1 | [ |
| Seeds/ | Antifungal | In vitro | Positive: ethanol 70%; amphotericin B and nystatin. | MIC: 9.7, 19.53, 78 and 39.06 µg/mL, respectively | [ | |
| Seeds/Ethanol | Antifungal and Cytotoxicity | In vitro | Positive: ethanol 70% | MIC: 9.7; 19; 78 and 4.8 µg/mL, respectively; toxicity at concentrations of 1000; 500 and e 250 µg/mL | [ | |
| Leafs/Water | Antifungal | In vitro | Positive: captan | Up to 96% inhibition at a concentration of 0.075 mg.mL−1 | [ | |
| Leafs/Alcohol | Antifungal | In vitro | Positive: captan | 100% inhibition of symptoms in treated seeds | [ | |
| Stem bark/Water, Ethanol and acetone | Antifungal | In vitro | Positive: terbinafine | MIC: 62.5 and 31.3 μg/mL, respectively | [ | |
| --- |
| Antifungal | In vitro | Negative: sterile distilled water | Inhibited mycelial growth by 85.6% at a concentration of 30% | [ |
| Leafs/Water | Wistar rats | Anti-inflammatory and antioxidant | In vitro | Negative: saline 0.9% | Effective doses: 100, 200 and 300 mg/kg; | [ |
| Seeds/Water or Ethanol (20 - 80%) | Swiss mice and mouse embryonic fibroblast 3T3 cell line | Anti-inflammatory, antioxidant, antinociceptive, and cytotoxicity | In vitro | Positive: diclofenac, cisplatin and ascorbic acid, and morphine | Effective doses: 50, 100 and 200 mg/kg; | [ |
| Pods/Alcohol and ethyl acetate | ACP02 gastric adenocarcinoma cell line | Antioxidant and antimetastatic | In vitro | Positive: doxorubicin | DPPH: IC50 74.36 and 116.10 μg/mL | [ |
| Leafs/Ethanol | HaCaT and Wistar rats | Antioxidant, cytotoxicity, and hypolipidemic activity | In vitro | Positive: trolox, etoposide, lipanthyl, respectively | ED50: 12.5 µg/mL, IC50, 114.4 µg/mL | [ |
| Leafs/Ethanol | Male Sprague–Dawley rats | Antioxidant, antihyperglycemic, and toxicity | In vitro | Positive: ascorbic acid | ED50: 12.45 µg/mL; reduced levels of liver function, serum glucose and a-amylase; non-toxic profile; | [ |
| Leafs/Ethanol | --- | Antioxidant | In vitro | Positive: trolox | DPPH: IC50 10.57 µg/mL e ABTS: IC50 2.77 µg/mL | [ |
| Leafs, branches and fruits/Ethanol and hexane | Antileishmanial | In vitro | Positive: pentamidine Negative: DMSO | Methanol extract from fruits and hexane from leaves: IC50 of 15.04 and 53.09 μg·mL−1 | [ | |
| Fruits/Ethanol | HT-29 e HEK-293 | Antiproliferative, apoptotic and antioxidant | In vitro | Negative: untreated cells | Effective doses: 25–100 μg/mL | [ |
| Barks and pods/Ethanol | B16F10 e NHF | Anti-wrinkle, anti-whitening and cytotoxicity | In vitro | Negative: IBMX 25 μM | Effective doses: 25 and 250 μg/mL | [ |
| Bark and seed/ethanol | Wistar rats | Acute toxicity maternal and fetal | In vivo | Positive: 0.9% saline solution | Increase in creatinine levels in maternal serum and morphological changes in the fetus | [ |
| Fruit/Ethanol | Toxicity | In vivo | Positive: water Negative: 1% propylene glycol | Concentrations of 25, 50, and 125 mg/L caused lethality in the embryos | [ | |
| Bark/Alcohol | Larvae of | Toxicity | In vitro 50, 100, 250, 500, 750, and 1000 µg/mL; 750 µg/mL for 24 h | Positive: sea water | CL50 of 822.6334 µg/mL | [ |
| Fruit/Alcohol | Wistar rats | Toxicity and healing activity | In vivo | Positive: chlorhexidine digluconate | Concentration of 12.5% exhibited epidermis constituted in all animals | [ |
| Seed/Ethanol | Genotoxicity | In vivo and In vitro | Negative: not exposed | Increase of 2.5× in the level of DNA strands breaks in erythrocytes exposed to doses of 5, 10, and 20 mg/L | [ | |
| Leafs/Ethanol | HepG-2, Hep2, MCF-7, and HCT-116 | Cytotoxicity | In vitro | Positive: not exposed | IC50 of 19.3, 20, 21.8, and 24.47 μg/mL, respectively | [ |
| Pods/Water | Meristematic roots cells of | Cytotoxic, genotoxic, and cytoprotective potential | In vitro | Positive: water | Cytotoxic at concentrations 1 g/500 mL and 1 g/1000 mL after times 24 and 48 h of exposure | [ |
| Pods |
| Healing activity | In vivo | Negative: glycerin and water | Ointment in 24% inhibited the lesion area | [ |
| Stem barks/NaOH | Wistar rats | Healing activity | In vivo | Positive: collagenase 0.1 mL; negative: NaCl 0.9% | Effective concentrations: contractions 0.025, 0.05, 0.75, and 0.1% | [ |
| Pods | Wistar rats | Healing activity | In vivo | Positive: ointment collagenase | Significant reduction in the lesion area | [ |
| Barks/Ethanol | --- | Photoprotective activity and antioxidant | In vitro | Positive: Ascorbic acid | SPF of 3.29 in concentration 0.100 mg/mL and IC50 27.53 µg/mL | [ |
| Stem barks/Methanol | --- | Arginase inhibitory activity | In vitro | Positive: Nor-NOHA | Inhibited 12.81% in the concentration 100 μg/mL | [ |
| Seeds/water | Swiss mice | Inhibition of the hemorrhagic activity | In vitro | Positive: crude venom + saline Negative: crude venom + plant extract + saline | Showed no activity | [ |
| Pods, bark and leafs/Methanol | Wistar rats | Edematogenic effect | In vivo | Negative: NaCl 0.9% | Effects at doses of 0.01–1 mg/kg | [ |
| Stem barks/Water | Human third molars | Erosive potential | In vitro | Positive: 1% citric acid | Loss of 37.03% dental enamel | [ |
| Fruit barks | Flies of the | Repellent action | In vivo | Positive: deteriorated bovine liver | Repellency of 97.5 and 100% in the concentrations 20 and 50% | [ |
| Leafs and pods/Water and methanol | Insecticidal activity | In vitro | Negative: 0.1% Tween 80 | Workers: CL50 0.255–1.279 mg·mL−1 | [ | |
| Leafs/Alcohol | Insecticidal activity | In vivo | Positive: insecticide | Efficiency of 51.71% | [ | |
| Leafs and pods/Water and methanol | Insecticidal activity | In vivo | Negative: 0.1% Tween 80 | 72.46–99.33% of mortality | [ | |
| Leafs and pods/Water and methanol | Insecticidal activity | In vivo | Positive: chlorpyrifos, acetamiprid and thiamethoxam | Nymphs: CL50 20–150 mg/mL | [ | |
| Leafs/Ethanol |
| Control of brown spot of Alternaria | In vitro 100, 50, 25, and 10 mg/mL for 10 days for 12 days | Positive: cibenzolar-S-methyl | Concentration of 500 μg/mL reduced in 52.0% the severity of disease | [ |
| Leafs/Water and ethanol |
| Control of brown spot of Alternaria | In vitro | Positive: acibenzolar-S-methyl | Concentration of 1 mg/mL reduced in 96.49 and 99.12% the severity of disease | [ |
| Leafs | Fertilizer | --- | --- | Increased the levels of potassium, calcium, and magnesium in the soil | [ | |
| Leafs and seeds/Ethanol | Seeds of | Allelopathic potential | In vitro | Positive: water | 30% abnormal seedlings at the concentration of 1% | [ |
| Leafs, barks and roots/Water | Allelopathic potential | In vitro | Negative: water | Inhibition of germination of both species | [ | |
| Dry leaves |
| Allelopathic potential | In vivo | Positive: water | Abnormalities in seedlings | [ |
| Fruits | Meio aquoso contendo MB | Biosorbent | --- | --- | Fast kinetics and good adsorption in the removal of MB | [ |
| Residues of pods | Captopril aqueous solutions | Biosorbent | Proportion of pod waste: ZnCl2 0.5: 1; 1: 1 and 1.5:1 | --- | 97.67% removal | [ |
MIC = Minimum Inhibitory Concentration; MBC = Minimum Bactericidal Concentration; MB = methylene blue; HT-29 = human colorectal cancer cell line; HEK-293 = embryonic renal cell line; NaOH = Sodium hydroxide; B16F10 = murine melanoma cell lines; NHF = normal human fibroblasts; HaCaT = keratinocyte cell line; IC50: Half Maximal Inhibitory Concentration; LC50: Median Lethal Concentration; ED50: Half Effective Maximum Dose; EC50: Half Maximal Effective Concentration; DPPH: 2,2-Diphenyl-1-picrylhydrazyl radical; ABTS: 2,2’-azino-bis (3-ethylbenzothiazoline); IBMX: 3-isobutyl-1-methylxanthine; RPMI: Roswell Park Memorial Institute (cell culture medium).
Biological activities of compounds isolated from C. ferrea extracts.
| Compound | Target or Model | Bioactivities Evaluated | Formulations/Dosage | Control(s) | Results | Citations |
|---|---|---|---|---|---|---|
| Galactomannan | Wistar rats | Antihyperglycemic and toxicity | In vivo10 mg/kg for 5 weeks | Positive: non-diabetic animals | Efficient dose of 10 mg/kg; No toxicity | [ |
| Sulfated galactomannan | DENV-2 virus in Vero cells | Antiviral, antioxidant and cytotoxicity | In vitro | Positive: Vero cells infected DENV-2 | 96% inhibition against DENV-2 in the concentration of 25 g/mL; IC50 of 0.94 μg/mL | [ |
| Brevifolin carboxylic acid | HaCaT | Antioxidant and cytotoxicity | In vitro | Positive: Not exposed | ED50 5 µg/mL and IC50 124.9 μg/mL | [ |
| 2″-O-Galloylorientin | HaCaT | Antioxidant and cytotoxicity | In vitro | Positive: Not exposed | ED50 1.9 µg/mL and IC50 67.5 μg/mL | [ |
| 2″-O-Galloylvitexin | HaCaT | Antioxidant and cytotoxicity | In vitro | Positive: Not exposed | ED50 3.8 µg/mL and IC50 59.7 μg/mL | [ |
| 2″-O-Galloylvitexin | HepG-2, HCT-116, Hep2 and MCF-7 | Cytotoxicity | In vitro | Positive: Not exposed | IC50: 18.5; 22.6; 24.2 and 28.4 μg/mL, respectively | [ |
HaCaT = keratinocyte cell line; liver HepG-2, larynx Hep2, colon HCT-116, breast MCF-7 and prostate PC3, human cell line; ED50: Half Effective Maximum Dose; IC50: Half Maximal Inhibitory Concentration.